Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on Corline Heparin Conjugate (CHC) technology, a naturally occurring biomolecule heaparin, which is routinely used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting. It offers CHS stent, a metallic tube-shaped device for the treatment of acute or threatened vessel closure during coronary angioplasty; CHS Coated Ablation Catheter to treat heart arrythmia; Renaparin for use in the treatment of end stage renal failure; and CHC, which is used for the treatment of soft tissue injuries. Corline Biomedical AB was incorporated in 1991 and is based in Uppsala, Sweden.
Frequently asked questions
What sector does Corline Biomedical AB (CLBIO) operate in?
Corline Biomedical AB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Corline Biomedical AB (CLBIO) current stock price?
As of the latest data, Corline Biomedical AB stock price is SEK 18.15, with a previous close of SEK 18.20. Corline Biomedical AB lost -SEK 0.05 in the last trading session, representing a -0.27% loss.
What is Corline Biomedical AB (CLBIO) current market capitalization?
Corline Biomedical AB market cap is approximately 474.32 million.
What is Corline Biomedical AB (CLBIO) Earnings Per Share (EPS)?
The trailing EPS is -SEK 0.56.
What is Corline Biomedical AB (CLBIO) EBITDA?
Corline Biomedical AB EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -2.41 million.
Does Corline Biomedical AB (CLBIO) pay dividends?
No. Corline Biomedical AB does not pay a dividend.
What is Corline Biomedical AB (CLBIO) beta (volatility) score?
Corline Biomedical AB has a beta of 0.319, indicating lower volatility than the overall market.
